If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

The deadline for investors with losses to be considered by the court to serve as Lead Plaintiff is August 25, 2025. Hagens Berman urges Sarepta investors who suffered substantial losses to submit your ...

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

The confluence of legal challenges, regulatory setbacks, and financial strain presents an existential threat. Sarepta's ability to withstand this perfect storm will be determined in the near term, ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.